Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia (SHASTA-3)
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia
Sponsor: Arrowhead Pharmaceuticals
Listed as NCT06347003, this PHASE3 trial focuses on Severe Hypertriglyceridemia and remains ongoing. Sponsored by Arrowhead Pharmaceuticals, it has been updated 14 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2025 — Aug 2025 [monthly]
Recruiting PHASE3
▶ Show 9 earlier versions
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Arrowhead Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alba Iulia, Romania , Baltimore, United States , Banská Bystrica, Slovakia , Baotou, China , Barcelona, Spain , Bardejov, Slovakia , Beijing, China , Belo Horizonte, Brazil , Belém, Brazil , Bengbu, China and 146 more locations